ArticlePsychopharmacology2026
Alpha-pinene modulates hippocampal MAPKs/c-Fos pathways during morphine dependence and withdrawal in rats.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleA potential strategy for managing morphine addiction is preventing mitogen-activated protein kinases (MAPKs) activation and neuroinflammation. The molecular basis of inflammation involves inflammatory cytokines, whose production and activity are modulated by the MAPKs signaling pathways.
objectivesThis study investigated how alpha-pinene (APN), an anti-inflammatory monoterpene, influences hippocampal MAPKs levels during chronic morphine exposure and the subsequent prolonged withdrawal phase.
methodsThree experimental groups as dependent model groups intraperitoneally received 10 days of saline + DMSO, morphine (10 mg/kg) + DMSO, and morphine + APN (20 mg/kg). Three additional groups were designated as withdrawal models, treating them with either saline (group 1) or morphine (groups 2 and 3) for 10 days before subjecting them to a 30-day withdrawal period. During the withdrawal, the first and second groups were administered daily 5% DMSO injections, whereas the third group received daily APN (20 mg/kg) treatment. Results: The results revealed that Hippocampal expression of MAPKs, including p38, ERK1/2, and JNK remained largely unchanged subsequent to both the chronic morphine exposure and the 30-day morphine wash-out phase. However, hippocampal levels of the phosphorylated form of the MAPKs significantly increased after both the morphine exposure and withdrawal phase. Interestingly, APN treatment during morphine exposure or over the 30-day of withdrawal phase significantly restored hippocampal levels of the phosphorylated MAPKs and decreased c-Fos expression.
conclusionsIt can be concluded that APN treatment may contribute to preventing hippocampal MAPK overactivation and decreasing c-Fos expression resulting from chronic morphine exposure and the subsequent withdrawal phase.
Indexed as
Identifiers
41760778What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.